Table 1.

Baseline characteristics of 134 NOVA cohort study participants.

	n or median	Percent or IQR
Age in years	36	28–47
Gender
Male	130	97.0%
Female	4	3.0%
Region of birtha
Europe	103	77.4%
Caribbean	10	7.5%
South America	10	7.5%
Other	10	7.5%
MSM
Yes	117	87.3%
No	6	4.5%
Unknown	11	8.2%
Site of HIV diagnosis
STI clinic	65	48.5%
General practice	39	29.1%
Hospital	18	13.4%
Otherb	8	6.0%
Unknown	4	3.0%
Subtype
B	98	73.1%
Non-B	36	26.9%
A	10
CRF02_AG	7
C	6
CRF01_AE	5
F	4
CRF06_cpx	2
CRF47_BF	1
G + CRF02_AGc	1
Fiebig stage
I	3	2.2%
II	17	12.7%
III	5	3.7%
IV	37	27.6%
V	39	29.1%
VId	19	14.2%
Unknown	14	10.4%
Plasma viral load (log10 copies/ml)e	5.8	4.7–6.7
CD4+ T-cell count (cells/μl)f	510	355–683
CD8+ T-cell count (cells/μl)g	941	550–1485
CD4+/CD8+ T-cell ratioh	0.5	0.4–0.9

ART, antiretroviral therapy; IQR, interquartile range; STI; sexually transmitted infection.

^a1 value missing.

^bCommunity-based testing (n = 4), own initiative (n = 4).

^cG + CRF02_AG was based on a best match (4.52%) with this subtype according to the Stanford University HIV Drug Resistance Database [12].

^dParticipants diagnosed in Fiebig VI could only be included in case of a negative test result available in the previous six months.

^eFour values missing.

^fFour values missing.

^gFive values missing.

^hFive values missing.